Elicio (ELTX) CEO Robert Connelly Receives Stock Option Award

What Happened Robert Connelly, CEO, President and Director of Elicio Therapeutics (ELTX), received a derivative award covering 186,944 shares on July 16, 2026. The grant is reported at $0.00 per share (award/derivative), indicating an option/award rather than a cash purchase; no immediate cash value or exercise price is shown in the provided excerpt.

Key Details

• Transaction date: 2026-07-16; Form 4 filed 2026-07-17 (timely).
• Transaction type/code: A (Grant, award or other acquisition — derivative security).
• Quantity: 186,944 derivative securities (options/awards) acquired at $0.00 per share in the filing excerpt.
• Vesting: 50% vests and becomes exercisable on July 16, 2027; remaining 50% vests on July 16, 2028, subject to continued service (per footnote).
• Exercise price / total grant value: Not disclosed in the provided excerpt.
• Shares owned after transaction: Not specified in the provided excerpt.
• Filing status: Timely (no late filing indicated).

Context This was a compensation grant to the CEO (an award of derivative securities/options) rather than an open-market buy or sale. Such grants are commonly used to align executive incentives with shareholder value; they do not represent an immediate cash investment or sale. There is no indication from this filing that any shares were exercised or sold.